Reduced platelet hyperreactivity and plateletmonocyte aggregation in HIV-infected individuals receiving a raltegravir-based regimen

AIDS

Volumn 28, Issue 14, 2014, Pages 2091-2096

  Tunjungputri, Rahajeng N ^a,b   Van Der Ven, Andre J ^a   Schonsberg, Anna ^a   Mathan, Till S ^a   Koopmans, Peter ^a   Roest, Mark ^c   Fijnheer, Rob ^c   Groot, Philip G D E ^c   De Mast, Quirijn ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DIPONEGORO UNIVERSITY   (Indonesia)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiovascular; HIV; Platelet; Platelet monocyte aggregation; Raltegravir

Indexed keywords

ADENOSINE DIPHOSPHATE; ATAZANAVIR; BIOLOGICAL MARKER; CD14 ANTIGEN; DARUNAVIR; EFAVIRENZ; FIBRINOGEN; GLYCOPROTEIN IB ALPHA; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PADGEM PROTEIN; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; 2 PYRROLIDONE DERIVATIVE; ANTITHROMBOCYTIC AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL AGGREGATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFLAMMATION; MALE; NONHUMAN; PLATELET MONOCYTE AGGREGATION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS INHIBITION; BLOOD; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DRUG EFFECTS; HIV INFECTIONS; MONOCYTE; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; THROMBOCYTE; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

BLOOD PLATELETS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HUMANS; MONOCYTES; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRROLIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84906726960     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000415     Document Type: Article

References (43)

1. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145: 397-406.
2. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-622.
3. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012; 9: 139-147.
4. Hansson GK. Inflammation atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
5. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
6. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-67.
7. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003; 101: 2661-2666.
8. Harrison P, Keeling D. Platelet hyperactivity and risk of recurrent thrombosis. J Thromb Haemostasis 2006; 4: 2544-2546.
9. Angiolillo DJ, Bernardo E, Sabaté M, Jimenez-Quevedo P, Costa MA, Palazuelos J, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50: 1541-1547.
10. Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-Alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest 1995; 95: 2297-2303.
11. May AE, Langer H, Seizer P, Bigalke B, Lindemann S, Gawaz M. Platelet-leukocyte interactions in inflammation and atherothrombosis. Semin Thromb Hemost 2007; 33: 123-127.
12. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010; 30: 2357-2361.
13. Freedman JE, Loscalzo J. Platelet-monocyte aggregates bridging thrombosis inflammation. Circulation 2002; 105: 2130-2132.
14. Kopp CW, Gremmel T, Steiner S, Seidinger D, Minar E, Maurer G, et al. Platelet-monocyte cross talk and tissue factor expression in stable angina vs. unstable angina/non ST-elevation myocardial infarction. Platelets 2011; 22: 530-536.
15. Mayne E, Funderburg NT, Sieg SF, Asaad R, Kalinowska M, Rodriguez B, et al. Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr 2012; 59: 340-346.
16. Holme PA, Muller F, Solum NO, Brosstad F, Froland SS, Aukrust P. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J 1998; 12: 79-89.
17. Satchell CS, Cotter AG, O'Connor EF, Peace AJ, Tedesco AF, Clare A, et al. Platelet function and HIV: a case-control study. AIDS 2010; 24: 649-657.
18. von Hentig N, Forster AK, Kuczka K, Klinkhardt U, Klauke S, Gute P, et al. Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors. J Antimicrob Chemother 2008; 62: 1118-1121.
19. Pate KAM, Lyons CE, Dorsey JL, Shirk EN, Queen SE, Adams RJ, et al. Platelet activation and platelet-monocyte aggregate formation contribute to decreased platelet count during acute simian immunodeficiency virus infection in pig-Tailed macaques. J Infect Dis 2013; 208: 874-883.
20. Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 2013; 208: 1436-1442.
21. Silva EF, Charreau I, Gourmel B, Mourah S, Kalidi I, Guillon B, et al. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. J Infect Dis 2013; 208: 892-897.
22. van Bladel ER, Laarhoven AG, van Der Heijden LB, Heitink-Pollé KM, Porcelijn L, van Der Schoot CE, et al. Functional platelet defects in children with severe chronic ITP as tested with two novel assays applicable for low platelet counts. Blood 2014; 123: 1556-1563.
23. Michels M, Alisjahbana B, De Groot PG, Indrati AR, Fijnheer R, Puspita M, et al. Platelet function alterations in dengue are associated with plasma leakage. Thromb Haemost 2014[Epub ahead of print].
24. Evangelista V, Manarini S, Sideri R, Rotondo S, Martelli N, Piccoli A, et al. Platelet/polymorphonuclear leukocyte interaction: p-selectin triggers protein-Tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule. Blood 1999; 93: 876-885.
25. Satchell CS, O'Halloran JA, Cotter AG, Peace AJ, O'Connor EF, Tedesco AF, et al. Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy. J Infect Dis 2011; 204: 1202-1210.
26. Haugaard AK, Lund TT, Birch C, Rönsholt F, Trøseid M, Ullum H, et al. Discrepant coagulation profile in HIV infection: elevated D-dimer but impaired platelet aggregation and clot initiation. AIDS 2013; 27: 2749-2758.
27. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-622.
28. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110: 1392-1397.
29. Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166-2171.
30. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1002-1006.
31. van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leuk Biol 2009; 85: 195-204.
32. Massberg S, Schürzinger K, Lorenz M, Konrad I, Schulz C, Plesnila N, et al. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia an in vivo study in mice lacking glycoprotein IIb. Circulation 2005; 112: 1180-1188.
33. Martinez E, D'Albuquerque PM, Llibre JM, Gutierrez F, Podzamczer D, Antela A, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012; 26: 2315-2326.
34. Perez-Matute P, Perez-Martinez L, Blanco JR, Oteo JA. Neutral actions of Raltegravir on adipogenesis, glucose metabolismand lipolysis in 3T3-L1 adipocytes. Curr HIV Res 2011; 9: 174-179.
35. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16: 460-465.
36. Massanella M, Esteve A, Buzon MJ, Llibre JM, Puertas MC, Gatell JM, et al. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification. J Acquir Immune Defic Syndr 2013; 7: 7.
37. Youssefian T, Drouin A, Masse JM, Guichard J, Cramer EM. Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. Blood 2002; 99: 4021-4029.
38. Violi F, Calvieri C, Ferro D, Pignatelli P. Statins as antithrombotic drugs. Circulation 2013; 127: 251-257.
39. Serebruany VL, Miller M, Pokov AN, Malinin AI, Lowry DR, Tanguay J-F, et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (From the PAR-1 Inhibition by Statins [PARIS] Study). Am J Cardiol 2006; 97: 1332-1336.
40. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
41. O'Brien M, Montenont E, Hu L, Nardi MA, Valdes V, Merolla M, et al. Aspirin attenuates platelet activation and immune activation in HIV-infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr 2013; 63: 80-88.
42. Xiao Z, Théroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 1982-1988.
43. van Bladel ER, de Jager RL, Walter D, Cornelissen L, Gaillard CA, Boven LA, et al. Platelets of patients with chronic kidney disease demonstrate deficient platelet reactivity in vitro. BMC Nephrol 2012; 13: 127.